G-Ã Rivard

List of Publications by Year
in descending order

70	2,109	279798	233421
papers	citations	23 h-index	45 g-index

70	70	70	1928
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Evaluation of antiâ€factor VIII antibodies in haemophilia A subjects switching products following a provincial tender. Haemophilia, 2022, 28, .	2.1	1
2	Quantitation of a plasma biomarker profile for the early detection of Gaucher disease type 1 patients. Bioanalysis, 2022, 14, 223-240.	1.5	0
3	Picomolar Sensitivity Analysis of Multiple Bradykinin-Related Peptides in the Blood Plasma of Patients With Hereditary Angioedema in Remission: A Pilot Study. Frontiers in Allergy, 2022, 3, 837463.	2.8	3
4	Management of a Left Atrial Appendage Thrombus Due to Atrial Fibrillation Complicating QuÃ©bec Platelet Disorder. Canadian Journal of Cardiology, 2022, 38, 1464-1466.	1.7	2
5	The diagnosis of a haemophilia A carrier over 2 decades. Haemophilia, 2021, 27, e133-e136.	2.1	1
6	A prospective surveillance study in haemophilia B patients following a population switch to recombinant factor IX (nonacog gamma). Haemophilia, 2021, 27, e530-e533.	2.1	0
7	Patterns of joint damage in severe haemophilia A treated with prophylaxis. Haemophilia, 2021, 27, 666-673.	2.1	1
8	Glanzmann Thrombasthenia: Perspectives from Clinical Practice on Accurate Diagnosis and Optimal Treatment Strategies. Journal of Blood Medicine, 2021, Volume 12, 449-463.	1.7	9
9	A full molecular picture of F8 intron 1 inversion created with optical genome mapping. Haemophilia, 2021, 27, e638-e640.	2.1	4
10	Predictive significance of antiâ€FVIII immunoglobulin patterns on bleeding phenotype and outcomes in acquired hemophilia A: Results from the Quebec Reference Center for Inhibitors. Journal of Thrombosis and Haemostasis, 2021, 19, 2947-2956.	3.8	4
11	Immune tolerance induction using Fcâ€fusionâ€protein recombinant factor IX in severe haemophilia B. Haemophilia, 2021, 27, e776-e779.	2.1	0
12	Magnetic resonance imaging in boys with severe hemophilia A: Serial and endâ€ofâ€study findings from the Canadian Hemophilia Primary Prophylaxis Study. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12565.	2.3	4
13	Initial Clinical Presentation and Predictors of Thrombotic Thrombocytopenic Purpura in Quebec. Blood, 2021, 138, 4224-4224.	1.4	0
14	Incidence of Thrombotic Microangiopathies in Quebec: An 8-Year Overview from a Laboratory Centralizing Adamts-13 Testing. Blood, 2021, 138, 4222-4222.	1.4	0
15	Improved platelet counts during prolonged tranexamic therapy for Quebec platelet disorder implicate the underlying fibrinolytic defect as the cause of lower platelet counts. International Journal of Laboratory Hematology, 2020, 42, e274-e276.	1.3	2
16	Enhancer-gene rewiring in the pathogenesis of Quebec Platelet Disorder. Blood, 2020, 136, 2679-2690.	1.4	13
17	The challenge of genetically unresolved haemophilia A patients: Interest of the combination of whole F8 gene sequencing and functional assays. Haemophilia, 2020, 26, 1056-1063.	2.1	11
18	In Vitro Modeling of Bradykinin-Mediated Angioedema States. Pharmaceuticals, 2020, 13, 201.	3.8	5

#	Article	IF	Citations
19	Identification of a Reliable Biomarker Profile for the Diagnosis of Gaucher Disease Type 1 Patients Using a Mass Spectrometry-Based Metabolomic Approach. International Journal of Molecular Sciences, 2020, 21, 7869.	4.1	11
20	Measurement of Bradykinin Formation and Degradation in Blood Plasma: Relevance for Acquired Angioedema Associated With Angiotensin Converting Enzyme Inhibition and for Hereditary Angioedema Due to Factor XII or Plasminogen Gene Variants. Frontiers in Medicine, 2020, 7, 358.	2.6	17
21	Confounding effect of therapeutic protamine and heparin levels on routine and special coagulation testing. Blood Coagulation and Fibrinolysis, 2020, 31, 60-64.	1.0	4
22	Challenges in diagnosis of von Willebrand disease in the presence of combined mutations of different genes. Haemophilia, 2019, 25, e113-e117.	2.1	0
23	Relapse pattern and longâ€term outcomes in subjects with acquired haemophilia A. Haemophilia, 2019, 25, 252-257.	2.1	11
24	Increased fibrinolysis-induced bradykinin formation in hereditary angioedema confirmed using stored plasma and biotechnological inhibitors. BMC Research Notes, 2019, 12, 291.	1.4	14
25	Acquired haemophilia A and concomitant factor XIII consumption. Haemophilia, 2019, 25, e180-e183.	2.1	1
26	Antithrombin and fibrinogen levels as predictors for plasma Lâ€asparaginase activity in children with acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2019, 66, e27729.	1.5	5
27	Synthetic anionic surfaces can replace microparticles in stimulating burst coagulation of blood plasma. Colloids and Surfaces B: Biointerfaces, 2019, 175, 596-605.	5.0	6
28	Thrombopoietin levels in Quebec platelet disorderâ€"Implications for the mechanism of thrombocytopenia. International Journal of Laboratory Hematology, 2018, 40, e33-e34.	1.3	4
29	A prospective surveillance study of inhibitor development in haemophilia A patients following a population switch to a thirdâ€generation Bâ€domainâ€deleted recombinant factor <scp>VIII</scp>. Haemophilia, 2018, 24, 236-244.	2.1	5
30	Challenges on the diagnostic approach of inherited platelet function disorders: Is a paradigm change necessary?. Platelets, 2018, 29, 148-155.	2.3	13
31	Vaccinations are not associated with inhibitor development in boys with severe haemophilia A. Haemophilia, 2018, 24, 283-290.	2.1	24
32	Management of acquired hemophilia A: Review of current evidence. Transfusion and Apheresis Science, 2018, 57, 717-720.	1.0	39
33	Management of acquired von Willebrand syndrome. Transfusion and Apheresis Science, 2018, 57, 721-723.	1.0	16
34	Comparing Pathways of Bradykinin Formation in Whole Blood From Healthy Volunteers and Patients With Hereditary Angioedema Due to C1 Inhibitor Deficiency. Frontiers in Immunology, 2018, 9, 2183.	4.8	13
35	Tailored frequency-escalated primary prophylaxis for severe haemophilia A: results of the 16-year Canadian Hemophilia Prophylaxis Study longitudinal cohort. Lancet Haematology,the, 2018, 5, e252-e260.	4.6	31
36	The GBA p.Trp378Gly mutation is a probable Frenchâ€Canadian founder mutation causing Gaucher disease and synucleinopathies. Clinical Genetics, 2018, 94, 339-345.	2.0	9

#	Article	IF	Citations
37	Molecular phenotype and bleeding risks of an inherited platelet disorder in a family with a <scp>RUNX</scp>1 frameshift mutation. Haemophilia, 2017, 23, e204-e213.	2.1	14
38	Effect of chitosan and coagulation factors on the wound repair phenotype of bioengineered blood clots. International Journal of Biological Macromolecules, 2017, 104, 1916-1924.	7.5	8
39	Severe bleeding diatheses in an elderly patient with combined type autoantibody against factor <scp>XIII</scp> A subunit; novel approach to the diagnosis and classification of antiâ€factor XIII antibodies. Haemophilia, 2017, 23, 590-597.	2.1	4
40	Effect of a Rapidly Degrading Presolidified 10 kDa Chitosan/Blood Implant and Subchondral Marrow Stimulation Surgical Approach on Cartilage Resurfacing in a Sheep Model. Cartilage, 2017, 8, 417-431.	2.7	6
41	The duplication mutation of Quebec platelet disorder dysregulates PLAU, but not C10orf55, selectively increasing production of normal PLAU transcripts by megakaryocytes but not granulocytes. PLoS ONE, 2017, 12, e0173991.	2.5	18
42	Alloantibody developed in a factor XIII A subunit deficient patient during substitution therapy; characterization of the antibody. Haemophilia, 2016, 22, 268-275.	2.1	15
43	Incidence of hypotension and acute hypotensive transfusion reactions following platelet concentrate transfusions. Vox Sanguinis, 2016, 110, 150-158.	1.5	4
44	Adherence to treatment regimen and bleeding rates in a prospective cohort of youth and young adults on low-dose daily prophylaxis for severe hemophilia A. BMC Hematology, 2016, 16, 26.	2.6	5
45	The isolated human umbilical vein as a bioassay for kinin-generating proteases: An in vitro model for therapeutic angioedema agents. Life Sciences, 2016, 155, 180-188.	4.3	6
46	Management of Labour and Delivery in a Patient With Acquired Factor VII Deficiency With Inhibitor: A Case Report. Journal of Obstetrics and Gynaecology Canada, 2016, 38, 160-163.	0.7	6
47	<scp>L</scp>â€Asparaginase lowers plasma antithrombin and mannanâ€bindingâ€lectin levels: Impact on thrombotic and infectious events in children with acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2015, 62, 1381-1387.	1.5	16
48	Experience with central venous access devices (<scp>CVAD</scp>s) in the Canadian hemophilia primary prophylaxis study (<scp>CHPS</scp>). Haemophilia, 2015, 21, 469-476.	2.1	13
49	Incidence and risk factors for inhibitor development in previously untreated severe haemophilia A patients born between 2005 and 2010. Haemophilia, 2014, 20, 771-776.	2.1	29
50	Immune tolerance induction in haemophilia A patients with inhibitors by treatment with recombinant factor VIII: a retrospective nonâ€interventional study. Haemophilia, 2013, 19, 449-455.	2.1	19
51	Simultaneous measurement of adenosine triphosphate release and aggregation potentiates human platelet aggregation responses for some subjects, including persons with Quebec platelet disorder. Thrombosis and Haemostasis, 2012, 107, 726-734.	3.4	19
52	An MRI scale for assessment of haemophilic arthropathy from the International Prophylaxis Study Group. Haemophilia, 2012, 18, 962-970.	2.1	111
53	Quebec platelet disorder. Expert Review of Hematology, 2011, 4, 137-141.	2.2	34
54	Persons with Quebec platelet disorder have a tandem duplication of PLAU, the urokinase plasminogen activator gene. Blood, 2010, 115, 1264-1266.	1.4	87

#	Article	IF	Citations
55	Increased expression of urokinase plasminogen activator in Quebec platelet disorder is linked to megakaryocyte differentiation. Blood, 2009, 113, 1535-1542.	1.4	40
56	Quebec platelet disorder is linked to the urokinase plasminogen activator gene (PLAU) and increases expression of the linked allele in megakaryocytes. Blood, 2009, 113, 1543-1546.	1.4	49
57	Low-dose ASA Response Using the PFA-100 in Women With High-risk Pregnancy. Journal of Obstetrics and Gynaecology Canada, 2009, 31, 1022-1027.	0.7	73
58	Efficacy of factor VIII/von Willebrand factor concentrate Alphanate^{Â®} in preventing excessive bleeding during surgery in subjects with von Willebrand disease. Haemophilia, 2008, 14, 271-275.	2.1	40
59	A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose. Haemophilia, 2008, 14, 281-286.	2.1	45
60	International workshop on immune tolerance induction: consensus recommendations. Haemophilia, 2007, 13, 1-22.	2.1	228
61	Chitosanâ€“glycerol phosphate/blood implants elicit hyaline cartilage repair integrated with porous subchondral bone in microdrilled rabbit defects. Osteoarthritis and Cartilage, 2007, 15, 78-89.	1.3	207
62	Insights into abnormal hemostasis in the Quebec platelet disorder from analyses of clot lysis. Journal of Thrombosis and Haemostasis, 2006, 4, 1086-1094.	3.8	47
63	Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. Journal of Thrombosis and Haemostasis, 2006, 4, 1228-1236.	3.8	224
64	Canadian multi-institutional survey of immune tolerance therapy (ITT) - experience with the use of recombinant factor VIII for ITT. Haemophilia, 2006, 12, 1-6.	2.1	38
65	Can activated recombinant factor VII be used to postpone the exposure of infants to factor VIII until after 2 years of age?. Haemophilia, 2005, 11, 335-339.	2.1	27
66	Bleeding risks associated with inheritance of the Quebec platelet disorder. Blood, 2004, 104, 159-165.	1.4	102
67	Immunoadsorption for coagulation factor inhibitors: a retrospective critical appraisal of 10 consecutive cases from a single institution. Haemophilia, 2003, 9, 711-716.	2.1	46
68	Platelets from patients with the Quebec platelet disorder contain and secrete abnormal amounts of urokinase-type plasminogen activator. Blood, 2001, 98, 257-265.	1.4	116
69	Surveillance for Factor VIII Inhibitor Development in the Canadian Hemophilia A Population Following the Widespread Introduction of Recombinant Factor VIII Replacement Therapy. Transfusion Science, 1998, 19, 139-148.	0.6	73
70	Circadian Time-Dependent Response of Childhood Lymphoblastic Leukemia to Chemotherapy: A Long-Term Follow-up Study of Survival. Chronobiology International, 1993, 10, 201-204.	2.0	57